Roxane recalls sodium polystyrene sulfonate suspension
Roxane has voluntarily recalled two lots of sodium polystyrene sulfonate suspension 15g/60mL unit dose bottles due to the presence of yeast. Currently there have been no reports of adverse events, but the presence of yeast may potentially affect immunocompromised patients.
Sodium polystyrene sulfonate suspension is indicated for the treatment of hyperkalemia.
For more information call visit www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm095023.htm.